Holen Sie sich die Stockscreener-App
2.315
3.94%
-0.095
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn
Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn
Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn
Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan
Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan
Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus
LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat
Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et
Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo
18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada
RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants - Stock Titan
Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21AI Trade Signals - vinanet.vn
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics, Inc. $IKT Position Boosted by Kalehua Capital Management LLC - MarketBeat
Inhibikase Therapeutics, Inc. Revenue Breakdown – BOATS:IKT - TradingView
IKT|Inhibikase Therapeutics Inc|Price:2.330| - TradingKey
TradingKey - TradingKey
IKT|Inhibikase Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires 25 Million Shares in Inhibi - GuruFocus
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation fr - GuruFocus
$Inhibikase Therapeutics (IKT.US)$ - Moomoo
Inhibikase Gains FDA Orphan Drug Status for IKT-001 - TipRanks
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation from FDA - GuruFocus
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - The Manila Times
Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
Inhibikase Therapeutics (IKT) Surges 7.4%: Testing Key Resistance at $2.45VWAP Bounce - vinanet.vn
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Q1 2026 Earnings: Better-Than-Expected Loss Buoys Shares After Market CloseShort-Term Outlook - vinanet.vn
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan
RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan
IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility - marketscreener.com
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm
Inhibikase raises $50M to fund PAH program - TipRanks
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Nigeria
Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo
Inhibikase raises $50 million through stock sale to RA Capital - Investing.com
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
1.01%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):